Airocide In Dialysis Centers
Your Kidney's help filter waste products from your blood, and in doing so keep you alive. When the Kidneys fail, a process called Dialysis is needed to perform their function. Dialysis is a life support mechanism that filters harmful waste from the blood. It is performed in rooms similar to the one pictured above.
Air quality in Dialysis rooms is very important for two reasons. One one hand; patients share a common space that leads to the easy spread of disease. Microbes (Bacteria, Fungi, and Virus) propagate through the air from one patient to another. On the other hand; equipment must remain sterile to prevent secondary infections. While normal sterilization techniques will prevent the spread of microflora on the surface of instruments, when exposed to contaminated air there is a risk of reintroduction. This risk is particularly acute given situations where patients may arrive ill. Airocide can help control both of these scenarios.
In the well respected Texas A&M Study Airocide was documented as reducing all classes of Bacteria. This alone will dramatically reduce incidents of infection to Dialysis patients. Likewise, Airocide removes fungal pathogens, such as Aspergillus. Fungal infections are particularly difficult to treat because of the genetic similarity between animals and fungi.
Dialysis centers, in the United States, are typically between 30,000 and 50,000 cubic feet. You will probably find this metric to be the same in your territory. The unit I recommend is the GCS-25. It is quieter than the other two units, and thus more conducive to creating a comfortable environment for patients who undergo dialysis. I can not stress enough how difficult it is for a person to undergo Dialysis, so please stress that Airocide has a solution that maintains comfort as well as air quality. You will need 10 GCS-25s for the smaller dialysis room, and 15 for the larger. This will reduce dramatically reported cases of cross-infection which occur in these locations. It is a great sale to boot. Furthermore, Dialysis centers are common, so this is a success you can replicate again and again.
This is a new and potentially lucrative market for Airocide. Airocide lacks a formal case study in a Dialysis center and having one would really help. So, I challenge you to not only get units into a Dialysis center but also help Airocide come up with a scientifically rigorous case study.
David A. Ghelerter
Chief Science and Technology Officer, Airocide